Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells.
OBJECTIVE: Trastuzumab has been used for the treatment of HER2-positive breast cancer (BC). However, a subset of BC patients exhibited resistance to trastuzumab therapy. Thus, clarifying the molecular mechanism of trastuzumab treatment will be beneficial to improve the treatment of HER2-positive BC...
Main Authors: | Takehiro Ichikawa, Fumiaki Sato, Kazuya Terasawa, Soken Tsuchiya, Masakazu Toi, Gozoh Tsujimoto, Kazuharu Shimizu |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3288043?pdf=render |
Similar Items
-
Synthetic Pre-miRNA-Based shRNA as Potent RNAi Triggers
by: Kazuya Terasawa, et al.
Published: (2011-01-01) -
The Roles of miR-26, miR-29, and miR-203 in the Silencing of the Epigenetic Machinery during Melanocyte Transformation
by: Cláudia Regina Gasque Schoof, et al.
Published: (2015-01-01) -
Association study of relationships of polymorphisms in the miR-21, miR-26b, miR-221/222 and miR-126 genes with cervical intraepithelial neoplasia and cervical cancer
by: Jia Yang, et al.
Published: (2021-09-01) -
Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients
by: Qiu Shuwei, et al.
Published: (2013-01-01) -
Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer
by: Schee Kristina, et al.
Published: (2012-11-01)